Nasus Pharma Ltd
No SEC Form 4 filings for $NSRX in the last 30 days.
See all $NSRX insider activity →Tyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.
Nasus Pharma Ltd. (NSRX) announced CFO Eyal Rubin's departure to pursue a new opportunity. Rubin will stay until September 18, 2026, to ensure a smooth transition. Oren Elmaliach, Director of Finance, has been appointed Interim CFO. Elmaliach has extensive financial experience and knowledge of the company's operations.
Nasus Pharma Ltd (NSRX) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update Appointed Pharma Industry Veteran Brendan O’Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, August
Over the past 7 days, AlphAI's AI scored 1 news story mentioning NSRX (Nasus Pharma Ltd). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent NSRX coverage spans financial news, market movers and corporate actions.
Regulatory clearance opens path to pivotal trial, enhancing pipeline value.
Potential short‑term stock volatility as investors assess leadership transition.
Positive cash infusion and clinical progress may support near‑term price appreciation, but net loss widening tempers upside.
Insider buying can be a modest sentiment tailwind, but this is not a fundamental catalyst like guidance, trial data, or financing.
Nasus Pharma's participation in investor conferences signals ongoing investor engagement but has limited immediate trading impact.
AlphAI scores every news story that mentions NSRX with an AI model for sentiment and relevance, and aggregates insider trades from Nasus Pharma Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Tyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.
3 min readNasus Pharma Ltd. (NSRX) announced CFO Eyal Rubin's departure to pursue a new opportunity. Rubin will stay until September 18, 2026, to ensure a smooth transition. Oren Elmaliach, Director of Finance, has been appointed Interim CFO. Elmaliach has extensive financial experience and knowledge of the company's operations.
1 min readNasus Pharma Ltd (NSRX) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update Appointed Pharma Industry Veteran Brendan O’Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, August
2 min readTeleman Dan Benjamin (Chief Executive Officer) purchased 6,550 shares of Nasus Pharma Ltd (NSRX) at $3.10 on 2026-06-17.
2 min readNasus Pharma, a clinical-stage pharmaceutical company, announced its participation in two upcoming investor conferences in May 2026. CFO Eyal Rubin will attend the "Market Movers Investor Summit" and the "D. Boral Capital Global Conference" in New York, engaging in one-on-one meetings with interested investors. The company focuses on developing innovative intranasal products, including NS002, an intranasal epinephrine product for anaphylaxis.
2 min readFunicular Funds, Cable Car Capital, and Jacob Ma-Weaver have collectively reported a 5.2% beneficial ownership stake in Nasus Pharma Ltd (NSRX), totaling 612,913 Ordinary Shares each. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment. The ownership calculation is based on 11,710,808 shares outstanding as of March 27, 2026.
2 min readTEL AVIV, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Nasus Pharma Ltd. ( NYSE:NSRX ) ( "Nasus Pharma", "Nasus" or the "Company" ) , a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the appointment ...
2 min readThe Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical study demonstrated NS002 can achieve faster and higher absorption of epinephrine compared to an autoinjector
3 min readTEL AVIV, Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Nasus Pharma Ltd. ( NYSE:NSRX ) ( "Nasus Pharma" or the "Company" ) , a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced that it recently ...
2 min read
